Serial combination therapy: is immune modulation in multiple sclerosis enhanced by initial immune suppression?

Abstract

Background

Although the concept that an initial course of immune-suppression facilitates subsequent immune-modulation (such as Th1 to Th2 deviation) is attractive for several autoimmune diseases, such a mechanism for serial-combination therapy has never been formally demonstrated. Recently, brief mitoxantrone induction-chemotherapy followed by immune-modulation with glatiramer acetate (GA) was significantly more effective at reducing multiple sclerosis disease activity than with GA alone.

Objective

To examine whether the benefit of initial immune suppression with mitoxantrone before GA treatment is associated with more efficient immune modulation.

Methods

IgG1/IgG4 GA-reactive antibody profiles, previously established as markers of GA-induced Th2 immune-deviation, were prospectively measured in vivo in patients treated with GA alone or with mitoxantrone induction therapy followed by GA.

Results

Significant and sustained increase in IgG4 antibodies (and the anticipated reversal of the IgG1/IgG4 ratio) was seen in patients treated with GA alone. Combination therapy resulted in lesser IgG4 induction (and no reversal of IgG1/IgG4 ratio). Thus, the enhanced efficacy of mitoxantrone–GA combination regimen was associated with decreased, rather than increased, efficiency of shifting the GA-reactive IgG1/IgG4 antibody profile.

Conclusion

These results provide important insights into mechanisms of combination therapy and therapeutic strategies for autoimmune diseases.

Keywords

B cells combination therapy GA-reactive antibodies glatiramer acetate IgG1-4 mitoxantrone multiple sclerosis Th2 immune-deviation

Get full access to this article

View all access options for this article.

References

1 Johnson KP Brooks BR Cohen JA . Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind, placebo-controlled trial. Neurology 1995; 45: 1268–1276.

2 Comi G Filippi M Wolinsky JS . ; European/Canadian Glatiramer Acetate Study Group. European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging – measured disease activity and burden in patients with relapsing multiple sclerosis. Ann Neurol 2001; 49: 290–297.

3 Filippi M Rovaris M Rocca MA Sormani MP Wolinsky JS Comi G . Glatiramer acetate reduces the proportion of new MS lesions evolving into "black holes". Neurology 2001; 57: 731–733.

4 Weber MS Hohlfeld R Zamvil SS . Mechanism of action of glatiramer acetate in treatment of multiple sclerosis. Neurotherapeutics 2007; 4: 647–653.

5 Bar-Or A . The immunology of multiple sclerosis. Semin Neurol 2008; 28: 5–21.

6 Duda PW Schmied MC Cook SL Krieger JI Hafler DA . Glatiramer acetate (Copaxone) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis. J Clin Invest 2000; 105: 967–976.

7 Farina C Then Bergh F Albrecht H . Treatment of multiple sclerosis with Copaxone (COP): elispot assay detects COP-induced interleukin-4 and interferon-gamma response in blood cells. Brain 2001; 124: 705–719.

8 Brenner T Arnon R Sela M . Humoral and cellular immune responses to Copolymer 1 in multiple sclerosis patients treated with Copaxone. J Neuroimmunol 2001; 115: 152–160.

9 Arnold DL Campagnolo D Panitch H . Glatiramer acetate after mitoxantrone induction improves MRI markers of lesion volume and permanent tissue injury in MS. J Neurol 2008; 255: 1473–1478.

10.

10 Vollmer T Panitch H Bar-Or A . Glatiramer acetate after induction therapy with mitoxantrone in relapsing multiple sclerosis. Mult Scler 2008; 14: 663–670.

11.

11 Stevens TL Bossie A Sanders VM . Regulation of antibody isotype secretion by subsets of antigen-specific helper T cells. Nature 1988; 334: 255–258.

12.

12 Farina C Vargas V Heydari N Kumpfel T Meinl E Hohlfeld R . Treatment with glatiramer acetate induces specific IgG4 antibodies in multiple sclerosis patients. J Neuroimmunol 2002; 123: 188–192.

13.

13 Basile E Gibbs E Aziz T Oger J . During 3 years treatment of primary progressive multiple sclerosis with glatiramer acetate, specific antibodies switch from IgG1 to IgG4. J Neuroimmunol 2006; 177: 161–166.

14.

14 McDonald WI Compston A Edan G . Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001; 50: 121–127.

15.

15 Duddy M Niino M Adatia F . Distinct effector cytokine profiles of memory and naive human B cell subsets and implication in multiple sclerosis. J Immunol 2007; 178: 6092–6099.

16.

16 Rissoan MC Soumelis V Kadowaki N . Reciprocal control of T helper cell and dendritic cell differentiation. Science 1999; 283: 1183–1186.

17.

17 Harris DP Haynes L Sayles PC . Reciprocal regulation of polarized cytokine production by effector B and T cells. Nat Immunol 2000; 1: 475–482.

18.

18 Chitnis T Salama AD Grusby MJ Sayegh MH Khoury SJ . Defining Th1 and Th2 immune responses in a reciprocal cytokine environment in vivo. J Immunol 2004; 172: 4260–4265.

19.

19 Miller A Shapiro S Gershtein R . Treatment of multiple sclerosis with copolymer-1 (Copaxone): implicating mechanisms of Th1 to Th2/Th3 immune-deviation. J Neuroimmunol 1998; 92: 113–121.

20.

20 Qin Y Zhang DQ Prat A Pouly S Antel J . Characterization of T cell lines derived from glatiramer-acetate-treated multiple sclerosis patients. J Neuroimmunol 2000; 108: 201–206.

21.

21 Tennakoon DK Mehta RS Ortega SB Bhoj V Racke MK Karandikar NJ . Therapeutic induction of regulatory, cytotoxic CD8+ T cells in multiple sclerosis. J Immunol 2006; 176: 7119–7129.

22.

22 Jee Y Piao WH Liu R . CD4(+)CD25(+) regulatory T cells contribute to the therapeutic effects of glatiramer acetate in experimental autoimmune encephalomyelitis. Clin Immunol 2007; 125: 34–42.

23.

23 Baecher-Allan C Hafler DA . Human regulatory T cells and their role in autoimmune disease. Immunol Rev 2006; 212: 203–216.

24.

24 Kantengwa S Weber MS Juillard C . Inhibition of naive Th1 CD4+ T cells by glatiramer acetate in multiple sclerosis. J Neuroimmunol 2007; 185: 123–129.

25.

25 Kim HJ Ifergan I Antel JP . Type 2 monocyte and microglia differentiation mediated by glatiramer acetate therapy in patients with multiple sclerosis. J Immunol 2004; 172: 7144–7153.

26.

26 Weber MS Starck M Wagenpfeil S Meinl E Hohlfeld R Farina C . Multiple sclerosis: glatiramer acetate inhibits monocyte reactivity in vitro and in vivo. Brain 2004; 127: 1370–1378.

27.

27 Weber MS Prod'homme T Youssef S . Type II monocytes modulate T cell-mediated central nervous system autoimmune disease. Nat Med 2007; 13: 935–943.

28.

28 Neuhaus O Wiendl H Kieseier BC . Multiple sclerosis: mitoxantrone promotes differential effects on immunocompetent cells in vitro. J Neuroimmunol 2005; 168: 128–137.

29.

29 Chan A Weilbach FX Toyka KV Gold R . Mitoxantrone induces cell death in peripheral blood leucocytes of multiple sclerosis patients. Clin Exp Immunol 2005; 139: 152–158.

30.

30 Rieger A Bar-Or A . B-cell-derived interleukin-10 in autoimmune disease: regulating the regulators. Nat Rev Immunol 2008; 8: 486–487.

31.

31 Bar-Or A Calabresi P Arnold DL . Rituximab in relapsing-remitting multiple sclerosis: a 72-week open-label trial. Ann Neurol 2008; 63: 395–400.

32.

32 Hauser SL Waubant E Arnold DL . B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 2008; 358: 676–688.

33.

33 Piao WH Wong R Bai XF . Therapeutic effect of anthracene-based anticancer agent ethionamide in an animal model of multiple sclerosis. J Immunol 2007; 179: 7415–7423.